Intellia Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Strong clinical trial results increase chances the drug gets approved and company becomes profitable.
Board members oversee company decisions, so their election affects how the business is run.
Quarterly reports show if the company is spending money wisely and getting closer to success.
New cash helps fund drug development and operating costs until products generate revenue.
Raising funds signals management believes the company needs more money to execute its plans.
First step in raising money shows company preparing to dilute existing shareholder ownership.
Stocky reads Intellia Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Intellia Therapeutics, Inc.'s most recent tracked filing was a 8-K on 15 Jun 2026: Lonvo-z shows 87% reduction in hereditary angioedema attacks.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.